Agenus Inc. (AGEN) is a Biotechnology company in the Healthcare sector, currently trading at $4.72. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is AGEN = $7 (+55.3% upside).
Valuation: AGEN trades at a trailing Price-to-Earnings (P/E) of 1290 (S&P 500 average ~25).
Financials: revenue is $114M, +12%/yr average growth. Net income is $115,000, growing at +39%/yr. Net profit margin is 0.1% (thin). Gross margin is 90.3% (+191.5 pp trend).
Balance sheet: total debt is $335M with negative equity of -$271M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 0.41 (tight liquidity). Debt-to-assets is 147.7%. Total assets: $227M.
Analyst outlook: 8 / 11 analysts rate AGEN as buy (73%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 46/100 (Partial), Growth 90/100 (Pass), Past 25/100 (Fail), Health 0/100 (Fail), Moat 58/100 (Partial), Future 85/100 (Pass), Income 30/100 (Fail).
